You are here: Home ยป Archives for NASDAQ

Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles

Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles

Mont–Saint–Guibert, Belgique – 19 décembre 2025, 10:05p.m. CET / 4:05p.m. ET – Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (AOS) par neuromodulation, a annoncé aujourd'hui l’émission de la première tranche du financement par obligations convertibles conclu avec une entité gérée par Heights Capital Management (« HCM ») jusqu’à €45 millions, comme annoncé précédemment par la Société le 13 novembre 2025.

Clôture de la première tranche de l’émission des obligations convertibles

Le 18 décembre 2025, la Société a émis la première tranche des obligations convertibles pour un montant nominale de €22.5 millions sous le contrat de souscription conclu avec HCM le 13 novembre 2025, tel que modifié le 16 décembre 2025. La première tranche consiste en l’émission de 225 obligations convertibles (les « Obligations de la Première Tranche ») avec une valeur nominale de €100,000 chacune, qui ont été entièrement souscrites et libérées par HCM. Conformément au contrat de souscription, la Société a payé des frais de souscription à HCM pour un montant total égal à 8% du montant initial des Obligations de la Première Tranche (i.e., €1.8 million), qui ont fait l’objet d’une compensation avec la partie correspondante du prix de souscription des Obligations de la Première Tranche dues par HCM.

Les Obligations de la Première Tranche portent intérêt au taux annuel de 6,5 % et ont une échéance de trois ans à compter de leur émission avec des remboursements trimestriels (chacune étant une « Date de Paiement d’Amortissement Prévue ») du montant initial (égal à un montant de €8.500 par Obligation de la Première Tranche, à l’exception du remboursement final qui sera égal à €6.500 par Obligation de la Première Tranche, chacun étant un « Montant de Paiement Amorti ») et de l’intérêt. La première Date de Paiement d’Amortissement Prévue sera le 18 février 2026.

Outre les remboursements prévus, HCM (ou tout futur détenteur de la majorité des Obligations de la Première Tranche) peut, à tout moment entre deux Dates de Paiement d'Amortissement Prévues (une « Période d'Amortissement Régulière »), exercer son droit d'avancer le paiement d'un maximum de deux Montants de Paiement Amortis à une date précisée dans un avis envoyé à la Société, qui ne peut être antérieure au troisième jour ouvrable suivant la date à laquelle l'avis pertinent est donné. En outre, HCM (ou tout futur détenteur de la majorité des Obligations de la Première Tranche) aura également le droit de reporter le paiement de tout Montant de Paiement Amorti à venir à toute Date de Paiement d'Amortissement Prévue ultérieure spécifiée dans l'avis envoyé à la Société.

HCM peut choisir de convertir le montant principal impayé des Obligations de Première Tranche ou chaque Montant de Paiement Amorti à tout moment pendant la durée des obligations. Le prix de conversion par défaut pour les Obligations de la Première Tranche, qui peut être modifié à la baisse, sera égal à €5.00, ce qui représente 125 % du prix de placement des actions émises dans le cadre du placement privé et de l’offre directe enregistrée annoncés précédemment (les « Augmentations de Capital »).

Chaque paiement des Montants de Paiement Amortis doit en principe être effectué en espèces pour un montant égal à 103 pour cent du montant initial d’un tel Montant de Paiement Amorti. Cependant, la Société peut choisir de satisfaire son obligation de payer le Montant de Paiement Amorti pertinent par l’émission de nouvelles actions ordinaires de la Société à HCM (l’ « Option de Règlement en Actions »). Au cas où la Société exerce son Option de Règlement en Actions, le prix d’émission des actions nouvelles ordinaires à émettre sera le plus bas des deux montants suivants: (a) le prix de conversion alors en vigueur et (b) 90 % du (i) prix moyen pondéré en fonction du volume d’une action ordinaire à la Date du Paiement d’Amortissement Prévue pertinente, et (ii) le plus bas des cinq prix moyens pondérés en fonction du volume d’une action ordinaire sur chacun des cinq jours de négociation consécutifs se terminant à (et incluant) cette Date du Paiement d’Amortissement Prévue.

De plus amples informations sur les Obligations de la Première Tranche sont disponibles dans le rapport spécial du conseil d'administration de la Société établi conformément aux articles 7:180, 7:191 et 7:193 du Code des sociétés et associations, disponible à l'adresse https://investors.nyxoah.com/financials.

Deuxième tranche des obligations convertibles

Conformément au contrat de souscription, la Société a l’option d’émettre une deuxième tranche des obligations convertibles (les « Obligations de la Deuxième Tranche ») à HCM pour un montant total maximal de €22.5 millions si demandé par la Société pendant la période entre le 18 juillet 2026 et le 18 août 2026.

La Société et HCM peuvent convenir par écrit d’un montant total inférieur à €22.5 millions pour les Obligations de la Deuxième Tranche.

L’obligation de HCM de souscrire aux Obligations de la Deuxième Tranche à la date de clôture des Obligations de la Deuxième Tranche (la « Date de Clôture de la Deuxième Tranche ») est soumise à certaines conditions préalables habituelles étant satisfaites (ou renoncé par HCM) avant ou à la Date de Clôture de la Deuxième Tranche. Plus précisément, il faut que, en outre:

        1. la moyenne arithmétique (arrondie au multiple entier le plus proche de U.S.$1.00 (U.S.$0.50 étant arrondi à la hausse)) des valeurs quotidiennes négociées des actions ordinaires de la Société pour chaque jour de bourse admissible compris dans la période de 60 jours de bourse admissibles consécutifs se terminant le jour de bourse admissible précédant immédiatement la date de l’avis de la Société d’émettre les Obligations de la Deuxième Tranche soit supérieure à U.S.$1 million (ou son équivalent dans toute autre devise); et
        1. la Société ait une dernière capitalisation boursière immédiatement avant la Date de Clôture de la Deuxième Tranche, et une capitalisation boursière moyenne sur chacun des 30 jours de négociation consécutifs terminant le jour de négociation immédiatement avant la Date de Clôture de la Deuxième Tranche (inclus), qui sont chacune supérieure à 240.000.000 €.

Au 16 décembre 2025, les conditions préalables relatives aux valeurs quotidiennes négociées, à la dernière capitalisation boursière et à la capitalisation boursière moyenne n’étaient pas remplies. Plus précisément, au 16 décembre 2025, la moyenne arithmétique des valeurs quotidiennes négociées s’élevait à U.S.$ 772,176, la dernière capitalisation boursière s’élevait à €177,053,883, et la capitalisation boursière moyenne sur 30 jours s’élevait à €175,959,735.

Les Obligations de la Deuxième Tranche seront, dans la mesure applicable, émis à des conditions substantiellement identiques que les Obligations de la Première Tranche. Le prix de conversion par défaut des Obligations de la Deuxième Tranche sera égal au plus bas des cinq prix moyens pondérés en fonction du volume des actions ordinaires de la Société sur Euronext Bruxelles à chacune des cinq jours de négociation se terminant à la Date de Clôture de la Deuxième Tranche.

Trésorerie

L’émission d’Obligations de la Première Tranche et la clôture des Augmentations de Capital ainsi que la deuxième tranche au titre de la facilité de crédit existante de la Société auprès de la Banque européenne d’investissement (dont la possibilité de tirage dépend d’un objectif de chiffre d’affaires que la Société prévoit d’atteindre au cours du premier semestre 2026), prolongeront la trésorerie de la Société jusqu’au troisième trimestre 2026. Si, en plus de ce qui précède, la Deuxième Tranche d’Obligations est émise, cela prolongerait la trésorerie disponible de la Société de deux trimestres, jusqu’au premier trimestre 2027.

Le produit net des Obligations de la Première Tranche ensemble avec le produit net des Augmentations de Capital, seront utilisés pour (i) lancer des activités de commercialisation aux États–Unis et faire progresser la commercialisation du système Genio sur ses marchés cibles initiaux en dehors des États–Unis; (ii) poursuivre la collecte de données cliniques et  soutenir les projets de recherche clinique initiés par des médecins et liés aux traitements des patients atteints d’AOS; (iii) financer davantage les activités de recherche et développement liées aux mises à niveau du système Genio, à la refonte de nos produits pour en améliorer la fabricabilité et à des initiatives de réduction des coûts; (iv) continuer à développer un pipeline de nouvelles technologies et à explorer les possibilités de collaboration dans le domaine de la surveillance et du diagnostic de l’AOS; et (v) à d’autres fins générales de l’entreprise, y compris, sans s’y limiter, le fonds de roulement, les dépenses en capital, les investissements, les acquisitions, si la Société décide de les poursuivre, et les collaborations.

Le présent communiqué de presse ne constitue pas une offre de vente ou la sollicitation d'une offre d'achat des titres, et il n'y aura pas de vente des titres dans un État où une telle offre, sollicitation ou vente serait illégale avant l'enregistrement ou la qualification en vertu des lois sur les valeurs mobilières de cet État.

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

INFORMATIONS IMPORTANTES

LE PRÉSENT COMMUNIQUÉ NE DOIT PAS ÊTRE DISTRIBUÉ, DIRECTEMENT OU INDIRECTEMENT, DANS UNE JURIDICTION OÙ CELA SERAIT INTERDIT PAR LA LOI. CE COMMUNIQUE EST UNIQUEMENT DESTINE A L'INFORMATION GENERALE ET NE FAIT PAS PARTIE D'UNE OFFRE DE VENTE OU D'ACHAT, OU DE LA SOLLICITATION D'UNE OFFRE DE VENTE OU D'ACHAT, DE VALEURS MOBILIERES. LA DISTRIBUTION DE CE COMMUNIQUE ET L'OFFRE, LA SOUSCRIPTION, LA VENTE ET L'ACHAT DES TITRES DECRITS DANS CE COMMUNIQUE DANS CERTAINES JURIDICTIONS PEUVENT ETRE RESTREINTES PAR LA LOI. TOUTE PERSONNE LISANT CETTE ANNONCE DOIT S'INFORMER DE CES RESTRICTIONS ET LES RESPECTER.

DÉCLARATIONS PROSPECTIVES

Certaines déclarations, convictions et opinions contenues dans le présent communiqué de presse sont prospectives et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le financement par obligations convertibles, le système Genio®; les études cliniques prévues et en cours sur le système Genio®; les avantages potentiels du système Genio®; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio® ; la stratégie de commercialisation de la Société et son entrée sur le marché américain; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la Société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, de manière non–exhaustive, la satisfaction des conditions requises pour la clôture des Obligations de la Deuxième Tranche, ainsi que la réalisation de la clôture respective, l’utilisation du produit net des Obligations de la Première Tranche, la suffisance attendue des ressources de trésorerie et la durée du financement de la Société, qui pourrait s'avérer inexacte et entraîner la nécessité d'un financement supplémentaire plus tôt que prévu, les risques et incertitudes énoncés dans la section « Risk Factors » du Annual Report on Form 20–F de la Société pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou les activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001145999)

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
First Genio implants successfully performed at OLVG West and Zuyderland hospitals

Mont–Saint–Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio® system in the Netherlands, marked by the first successful Genio implants performed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen.

Commenting on the introduction of Genio in Amsterdam, Dr. Peter van Maanen, ENT surgeon at OLVG West, stated: “Dr. Mayke Hentschel, our sleep department and I are pleased to offer our patients an additional treatment option for OSA when CPAP is not tolerated. With Genio, patients finally have a real choice. The system stimulates both branches of the nerve, has no internal battery, is full body 1.5 and 3T MRI–compatible, and can be easily upgraded via the external activation chip. These features make it a promising long–term solution for both patients and healthcare providers.”

At Zuyderland Hospital, Dr. Jos Straetmans, ENT surgeon in Heerlen and Sittard, added: “Introducing the Genio bilateral neurostimulation system expands our ability to tailor therapy to the needs of each individual patient. Its advantages: no implanted battery, and reliable performance in the supine position make it a valuable addition to our treatment arsenal. We are excited to bring this innovative, European developed technology to patients in our community.”

“The commercial launch of Genio in the Netherlands marks another important step in our European rollout and reflects growing adoption of our bilateral, externally powered Genio therapy,” commented Olivier Taelman, Nyxoah's Chief Executive Officer. “We are proud to partner with leading Dutch centers to bring Genio to patients seeking an effective and patient–centric alternative to CPAP. As we continue to expand our commercial footprint, these early implants further validate Genio’s role as a long–term solution for OSA.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centric, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001145284)

Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas

Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays–Bas
Premières implantations Genio réalisées avec succès dans les hôpitaux OLVG West et Zuyderland

Mont–Saint–Guibert, Belgique – 17 décembre 2025, 7h05 CET / 1h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui le lancement commercial de son système Genio® aux Pays–Bas, marqué par les premières implantations réussies de Genio à l'OLVG West d'Amsterdam et à l'hôpital Zuyderland de Heerlen.

Commentant l'introduction de Genio à Amsterdam, le Dr Peter van Maanen, chirurgien ORL à l'OLVG West, a déclaré : “Le Dr Mayke Hentschel, notre service du sommeil et moi–même sommes ravis d'offrir à nos patients une option thérapeutique supplémentaire pour le traitement de l'AOS lorsque la CPAP n'est pas tolérée. Avec Genio, les patients ont enfin un véritable choix. Le système stimule les deux branches du nerf, ne comporte aucune batterie interne, est compatible avec l'IRM 1,5 et 3T du corps entier et peut être facilement mis à jour via la puce d'activation externe. Ces caractéristiques en font une solution prometteuse à long terme pour les patients et les prestataires de soins de santé.”

À l'hôpital Zuyderland, le Dr Jos Straetmans, chirurgien ORL à Heerlen et Sittard, a ajouté : “L'introduction du système de neurostimulation bilatérale Genio élargit notre capacité à adapter le traitement aux besoins de chaque patient. Ses avantages : l'absence de batterie implantée et ses performances éprouvées en position dorsale en font un ajout précieux à notre arsenal thérapeutique. Nous sommes ravis de proposer cette technologie innovante, développée en Europe, aux patients de notre communauté.”

“Le lancement commercial de Genio aux Pays–Bas marque une nouvelle étape importante dans notre déploiement européen et reflète l'adoption croissante de notre thérapie bilatérale Genio à alimentation externe”, a commenté Olivier Taelman, CEO de Nyxoah. “Nous sommes fiers de nous associer à des centres néerlandais de premier plan pour proposer Genio aux patients qui recherchent une alternative efficace et centrée sur le patient à la CPAP. Alors que nous continuons à étendre notre présence commerciale, ces premières implantations confirment encore davantage le rôle de Genio en tant que solution à long terme pour le SAOS.”

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

DÉCLARATIONS PROSPECTIVES
Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001145284)

Zoom launches AI Companion 3.0 with agentic workflows, transforming conversations into action

  • Zoom’s new AI Companion web surface leverages work conversations to help save time and boost productivity
  • Personal workflows (beta), AI Companion 3.0 features for Zoom Docs (coming soon), and agentic AI features enhance work quality and streamline content creation
  • Free–tier and standalone plans enable Zoom Basic users to try AI Companion capabilities or purchase AI Companion as a standalone add–on without a separate paid Zoom Workplace license

SAN JOSE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Today, Zoom Communications, Inc. (NASDAQ: ZM) unveiled the next evolution of its agentic AI solution, Zoom AI Companion 3.0, including new AI–first capabilities for personal workflows (beta), agentic AI features for Zoom Docs (coming soon), and a new web interface with expanded context to help users uncover insights, optimize their day, and uplevel their work.

AI Companion 3.0 utilizes Zoom’s unique federated AI approach that combines the power of Zoom’s own LLMs and SLMs with leading third–party LLMs from OpenAI and Anthropic. Zoom users can also leverage leading open source models like NVIDIA Nemotron. This federated approach, combined with AI Companion’s ability to deliver better–quality results through more accurate transcription, closed captions, and translated captions, provides users with more relevant information retrieval and task completion.

“The launch of AI Companion 3.0 is a turning point for Zoom, continuing our transformation from a meeting company into a pioneer of AI–first intelligent work orchestration. By empowering our users with new AI Companion capabilities, we’re helping them get even more done so they can focus on connection,” said Velchamy Sankarlingam, president of Product and Engineering at Zoom. “Offering AI Companion’s newest capabilities both as a standalone option and within paid Zoom plans reflects our core belief of democratizing access to AI and providing users with intuitive solutions that can seamlessly understand their work context and help move conversations to completion.”

“AI Companion 3.0 is the type of solution people need to get work done,” said Kevin Kieller, co–founder and lead analyst at enableUC. “People need easy–to–use, consistent, consolidated solutions, and that’s exactly what Zoom is striving to deliver with AI Companion 3.0. Adopting this type of solution will help organizations be more efficient and collaborative, ultimately driving productivity across an organization.”

As AI Companion’s capabilities expand across new surfaces, Zoom continues its commitment to security, privacy, and responsible AI. Zoom encrypts customer data in transit between customers and Zoom, between Zoom data centers and third–party model providers, and at rest within Zoom’s platform. In line with Zoom’s commitment to transparency and privacy principles, Zoom does not use communications–like customer content to train its own or third–party models.

“AI Companion is changing the way teams at Oracle work, helping us turn conversations into clear next steps and actionable insights,” said Christine Sarros, senior vice president, Enterprise Engineering, Oracle Cloud Infrastructure. “We look forward to the upcoming AI Companion 3.0 release and the new capabilities it offers to further enhance collaboration and productivity.”

“Through our collaboration with Zoom on AI Companion 3.0, NVIDIA Nemotron open models are helping power the future of work,” said Kari Briski, vice president of generative AI software at NVIDIA. “Nemotron enables advanced reasoning and retrieval–augmented generation within Zoom’s federated AI stack, creating a private, powerful, and personalized work environment that enhances productivity for every enterprise customer.”

AI Companion can now be accessed from a desktop web browser at ai.zoom.us, making it even easier to transform rich meeting discussions into plans, briefs, and insights that help move work forward. Select AI Companion capabilities are also available for Zoom Workplace Basic users to try. They can also purchase AI Companion for $10 per month as a standalone, which does not require a paid Zoom Workplace license.

Conversational work surface uncovers insights from meetings

AI Companion helps people start their day with clarity and alignment, even when dealing with numerous post–meeting tasks and follow–ups. AI Companion’s new conversational work surface is connected to work interactions, transforming scattered meeting conversations and assets into insights, progress tracking, polished documents, and content without requiring users to upload meeting transcripts or additional documents or craft detailed prompts.

“At G42, we’re thrilled about the possibilities that Zoom AI Companion 3.0 brings to us,” said Ali Dalloul, CSO and Americas CEO at G42. “The new web–based work surface allows some of our divisions to experience Zoom’s agentic AI capabilities firsthand. It’s an exciting step toward a more connected, intelligent, and productive workplace.”

New AI Companion 3.0 features include:

  • Agentic retrieval capabilities, which can locate information across meeting summaries, transcripts, and notes in Zoom Workplace, as well as connected third–party apps, including Google Drive and Microsoft OneDrive, with Gmail and Outlook coming soon.
  • The Post Meeting Follow Up prompt template generates follow–up tasks and drafts email messages based on the meeting and to–do items.
  • The Daily Reflection Report prompt summarizes meetings, tasks, and updates to bring clarity to the workday, allowing users to focus on what matters.
  • Agentic writing mode helps draft, edit, and refine business documents based on specific meetings or resources, and edit alongside AI in a canvas interface.
  • Easily export to documents with a multitude of different file types, including MD, PDF, Microsoft Word, and Zoom Docs.
  • Continue editing and collaborating in Zoom Docs with teammates using shared commenting, version history, and co‑authoring tools.
  • Kick–start new initiatives with an AI brainstorming partner for projects and presentations.
  • For Custom AI Companion customers, deep research mode helps save time by analyzing multiple documents and meetings to generate comprehensive insights that power next steps.

Optimize workflows with enhanced notes and automated task management

Maximize engagement, collaboration, and decision clarity with new features to help streamline repetitive tasks and document, act on, and share important decisions.

  • With My Notes (coming soon), AI Companion can transcribe in–person meetings, Zoom Meetings, or meetings on other platforms, helping users keep track of critical details in one place.
  • Personal workflows (in beta) can help users stay on track by automatically executing follow–up tasks, such as compiling insights from meetings and documents to deliver a daily reflection report or automatically summarizing a user’s Team Chat threads and sending key highlights each morning. (Beta feature availability depends on account type; some usage limitations may apply.)
  • Users can start work on the web and seamlessly transition content to Zoom Docs or start within Zoom Docs, leveraging the same conversational, context–aware experience offered in the new AI Companion 3.0 web surface to create content and collaborate on projects with the new agentic writing and data table features (coming soon).

With AI Companion 3.0, Zoom continues to move beyond meetings to pioneer a new era of intelligent work orchestration, democratizing access to powerful AI capabilities across its platform. To learn more about AI Companion 3.0, visit the Zoom website.

About Zoom
Zoom (NASDAQ:ZM) provides the AI–first, open work platform built for human connection and purposefully designed to move conversations to completion. From entrepreneurs to global enterprises, customers choose Zoom to seamlessly collaborate, communicate, and drive outcomes across meetings, chat, phone, contact center, events, and more — all with the built–in assistance of Zoom AI Companion. Founded in 2011, Zoom is headquartered in San Jose, CA. For more information, visit zoom.com.

Zoom Public Relations
Lacretia Nichols
[email protected]


GLOBENEWSWIRE (Distribution ID 9602208)

Namib Minerals – Operational Update

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Namib Minerals Ltd. (“Namib” or the “Company”) today provided an operational update highlighting improving stability and cost performance across its producing asset as the Company approaches financial year–end.

Over the past 30 days, operational throughput has been maintained, reflecting a period of increased consistency in plant performance and mine operations. During this period,

  • on–mine all–in sustaining costs declined by approximately 8% month–on–month to US$2,140 per ounce,
  • while company–level AISC declined by approximately 11%, supported by sustained cost control measures and improving operational discipline.

Operational focus during this phase has been directed toward stability, predictable run–rates, cash discipline, and consistent cost management. Management noted that these efforts are contributing to improved cost visibility and execution reliability.

Safety performance remained strong during the period, with no reportable lost–time injuries recorded over the three months ended November, reflecting continued emphasis on operational discipline and workforce safety.

“Our priority has been to stabilise operations and establish predictable run–rates,” said Ibrahima Tall, Chief Executive Officer. “The improvements we are seeing reflect disciplined execution and provide a foundation for further optimisation as we continue through this consistency phase.”

The Company expects to continue providing operational updates as it progresses through this phase of performance stabilisation.

Forward–Looking Statements
This update includes forward–looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this update are forward–looking statements. Any statements that refer to estimates, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are also forward–looking statements. We caution you against placing undue reliance on forward–looking statements. 

About Namib Minerals
Namib Minerals (NASDAQ: NAMM) is a Gold producer, developer and explorer with operations focused in Zimbabwe. Namib Minerals is a significant player in Africa’s mining industry, driving sustainable growth and innovation across the sector. Currently Namib Minerals operates the How Mine, an underground Gold mine in Zimbabwe, and aims to restart two assets in Zimbabwe, with additional exploration assets in the DRC.
For additional information, please visit namibminerals.com

Contacts:

Investor Relations:
[email protected]  

Lamiaa Maniar
VP of Communications
[email protected]

No Offer or Solicitation
This press release shall not constitute an offer to sell or exchange, the solicitation of an offer to buy or a recommendation to purchase any securities, or a solicitation of any vote, consent or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale may be unlawful under the laws of such jurisdiction.


GLOBENEWSWIRE (Distribution ID 9602204)

Datavault AI Announces Hockey Hall of Famer Jeremy Roenick Joins to Monetize Sports Data and Lead Pioneering International NIL Exchange

PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) — Datavault AI Inc. (NASDAQ: DVLT; the “Company” or “Datavault AI”), a leading provider of patented agentic AI platforms for data observation, valuation and monetization, today announced that former NHL player and Hockey Hall of Famer Jeremy Roenick is advising the Company to spearhead the development of its groundbreaking Sports and Entertainment initiative with the forthcoming International NIL Exchange. This strategic move builds on Datavault AI’s recent partnerships in sports and entertainment, including its World Boxing Council and Dream Bowl initiatives, unlocking unprecedented event–driven monetization at scale.

Roenick, renowned for his larger–than–life career with over 1,200 NHL games, 513 goals, nine–time NHL All Star and induction into the Hockey Hall of Fame, will leverage his industry expertise to expand Datavault AI’s International NIL Exchange. The platform, powered by Datavault AI’s patented Data Vault, DataScore® and DataValue® AI agents, enables seamless indexing and tokenization of sports and entertainment assets using advanced data analytics. These tokenized assets will be traded on the patented Information Data Exchange® (IDE) platform via the New York Interactive Advertising Exchange (“NYAIX”) and the Nasdaq Financial Framework, providing athletes, entertainers and rights holders with secure, scalable revenue streams through smart contracts and real–time data valuation.

Jeremy Roenick stated, “Datavault AI is set to revolutionize how athletes and entertainers monetize their brands. The patented AI agents here are game–changers, indexing data to create tokenized assets that trade efficiently on a quantum secure exchange. This is about empowering creators with tools that deliver real financial power and global reach into the future. Extending my legacy in hockey for the young players of today, the legends of our past and for me in the broader sports and entertainment space where Datavault AI’s inventions in NIL have changed what’s possible.”

“Our Web 3.0 Data Vault Bank smart contracting platform empowers individuals to take immutable control of their own NIL,” Jeremy Roenick represents a pivotal advancement of talent driving Davault AI forward. “Our AI ecosystem is where data are transformed into tradable value and our NIL platform will be second to none featuring Nasdaq Financial Framework with NYAIX, the patented DataValue and DataScore engines and quantum encryption around assets. Jeremy Roenick is well–known for loving our new home of Philadelphia where he will always be a Flyer. This made him a natural selection by our team to be part of our vitally important mission,” said Nathaniel Bradley CEO of Datavault AI. “We envision together an exchange with the insight, foresight and oversight to solve NIL problems for good and to launch NIL for professional sports leagues their franchises as well as state, private colleges and universities. Our AI agents working for students, athletes and entertainers through Datavault AI focused on yield management, compliance and trading capabilities that will represent the next generation of competitive NIL [platforms].”

The International NIL Exchange aligns with Datavault AI’s core mission of harnessing AI and machine learning to automate third–party integrations, detailed data scoring and tokenized trading. Datavault AI’s technology suite is completely customizable, offering AI and machine learning automation for indexing and tokenizing assets, with trading facilitated on the patented IDE platform.

About Datavault AI

Datavault AITM (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud–based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry–first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi–channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high–performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud–based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real–world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third–party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.

Forward–Looking Statements

This press release includes “forward–looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward–looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward–looking. Such forward–looking statements, including, but not limited to, statements regarding future events; the expected benefits of Datavault AI’s International NIL Exchange; Datavault AI’s anticipated deployment of its International NIL Exchange; expectations regarding engagement levels, conversion rates, data capture volumes and monetization opportunities; potential revenue generation associated with authenticated audience interactions; the scalability of Datavault’s platforms across global sports properties, entertainment events or broadcast environments; Datavault AI’s business strategies, long–term objectives and commercialization plans; Datavault AI’s current and prospective technologies, planned developments and potential approvals; and the potential for market acceptance of Datavault AI’s platforms and related market opportunities, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward–looking statements contained herein.

Actual results may differ materially from those indicated by these forward–looking statements as a result of various risks and uncertainties including, but not limited to, the following: changes in market demand for digital engagement technologies; the performance, timing or success of Datavault AI’s deployment of the anticipated International NIL Exchange; the ability of sponsors, broadcasters and partners to adopt or integrate Datavault AI’s solutions; variations in audience participation levels, conversion rates or engagement behaviors; regulatory considerations related to data privacy, digital asset classification or international operations; risks related to technological development, interoperability, cybersecurity or system performance; changes in economic or market conditions affecting advertising, sponsorship or media–driven revenues; regulatory and intellectual property risks; and other risks and uncertainties as more fully described in Datavault AI’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10–K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

The forward–looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward–looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward–looking statements, and you should not place undue reliance on such forward–looking statements. Datavault AI’s forward–looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

Corporate Communications:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
 512.354.7000 Office
[email protected]

Media Inquiries:

[email protected]

© 2025 Datavault AI Inc. All Rights Reserved.


GLOBENEWSWIRE (Distribution ID 9602197)

Zoom Leads A Workplace Revolution

SAN JOSE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Today, on behalf of employees everywhere, Zoom announced the launch of a major brand campaign developed with Colin Jost’s No Notes Productions lampooning the technology everybody hates and inspiring users to stand up for what they really want. Starring SNL standout Bowen Yang, the “Zoom Ahead” campaign will debut on December 31 during the U.S. College Football Playoffs with the hero spot, I Use Zoom!, which taps into a universal truth — people just want technology that works for them. The campaign will continue with additional high–profile placements, including a Super Bowl pre–show placement on February 8, and will be supported by digital, social, and experiential activations throughout Spring 2026.

The campaign amplifies what users have made clear: Zoom’s AI–first platform beats the alternatives. Q3 FY26 NPS data tells the story: 22,000+ responses with an industry–leading score of 58, and over 70% praising simplicity, 40% citing reliability, and 100% of direct comparisons choosing Zoom Workplace over other tools. This momentum echoes industry recognition, as well: Zoom was recently named a Customers’ Choice in the Gartner® Peer Insights™ “Voice of the Customer” report and is one of only two companies positioned in both the UCaaS and CCaaS Magic Quadrants.

“I Use Zoom! resonates with audiences because it humorously delivers a truth familiar to everyone: don’t give us bad tools when Zoom makes work easier,” said Kimberly Storin, Chief Marketing Officer at Zoom. “The ‘Zoom Ahead’ campaign marks the first time we’re officially using ‘Zoom’ as a verb in our advertising. To ‘Zoom’ is already in the popular vernacular and signifies that the platform has become synonymous with getting things done.”

“Of all the virtual meeting options, Zoom definitely has the best brand name. I’ve never said, ‘Let’s do a Teams!’” said Colin Jost, founder of No Notes.

Directed by SNL’s Mike Diva, the spot blends the rebellion of Apple’s 1984 ad and the empowerment of Dead Poets Society into a dramatic uprising against clunky, overengineered tools. While satirizing the corporate monoliths that dictate which tech employees will use, it also celebrates the everyday employee finally standing up for their platform of choice.

“Zoom is no longer just a meetings app; it’s a complete, AI–first workplace platform built for people, not for complexity,” continued Storin. “The evolution of the Zoom platform has been dramatic — we’re leading the next generation of powerful, safe, and secure collaboration tools that are transforming business — and that’s a message people need to hear.”

The Zoom portfolio includes communication (Meetings, Team Chat, Phone), collaboration (Docs, Whiteboard, Tasks), productivity (Calendar, Mail), customer experience (Contact Center), sales & marketing (Webinars, Events, Revenue Accelerator), and AI Companion — all of which are designed to support how people actually work today.

To explore the “Zoom Ahead” campaign, visit www.zoom.com/resources/zoomahead.

About Zoom
Zoom (NASDAQ:ZM) provides the AI–first, open work platform built for human connection and purposefully designed to move conversations to completion. From entrepreneurs to global enterprises, customers choose Zoom to seamlessly collaborate, communicate, and drive outcomes across meetings, chat, phone, contact center, events, and more — all with the built–in assistance of Zoom AI Companion. Founded in 2011, Zoom is headquartered in San Jose, CA. For more information, visit zoom.com.

Press Contact
Rebecca Bernhard
[email protected]
[email protected]


GLOBENEWSWIRE (Distribution ID 9599874)

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

  • REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
  • After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baseline
  • Natural history analysis showed that 87% of untreated FAP patients – who resembled the inclusion criteria of TUPELO – had annualized polyp–burden increase, 10% remained stable, and 3% showed modest decrease—underscoring the disease’s progressive trajectory (n=55)
  • 40% of patients (4 out of 10) achieved a ≥1–point improvement in Spigelman stage—a clinically meaningful measure of upper GI disease severity to assess surveillance and clinical management
  • REC–4881 (4 mg QD) has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment–related adverse events being Grade 1 or 2, Grade 3 events occurring in 15.8% of the safety–evaluable patients, and no Grade ≥4 TRAEs reported to date
  • First clinical validation of the Recursion OS, demonstrating how unbiased phenotypic and mechanistic insights—such as MEK1/2 rescue of APC loss–of–function—can translate to novel, differentiated therapeutics for diseases like FAP with no approved therapy and high prevalence of >50,000 patients in US and EU5
  • Next steps: Engage the FDA in the 1H26 to define a potential registration pathway, and in parallel, expand the population from ≥55 to ≥18 years old, and further optimize dosing schedule

SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical–stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC–4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP).

Through an unbiased phenotypic screen of thousands of compounds, the earliest version of the Recursion OS identified selective MEK1/2 inhibition as a highly specific mechanism capable of reversing APC loss–of–function signatures. Using high–content cellular phenomics driven by AI, REC–4881 emerged as one of the strongest phenotypic rescue hits, reverting APC–deficient cells toward a healthy state and suppressing ERK/MAPK hyperactivation downstream of APC loss. Guided by this AI–driven insight, Recursion in–licensed REC–4881 from Takeda and redirected REC–4881—originally evaluated clinically in solid tumors—as a mechanistically aligned therapeutic candidate for FAP. REC–4881 is now the first MEK1/2 inhibitor ever studied clinically for this disease.

“The durable polyp burden reduction demonstrated by REC–4881—especially the sustained effect seen at Week 25, 12 weeks after completing therapy—is highly encouraging for the FAP community,” said Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine, and Principal Investigator of the TUPELO study. “Given the near–100% lifetime risk of colorectal cancer and the absence of any approved medical therapies, patients today often face a lifetime of intensive surveillance and life–altering surgeries. These Phase 2 results provide a meaningful basis for hope and support the potential for REC–4881 to offer a much–needed non–surgical option for this debilitating, life–long disease.”

“These Phase 2 results mark a meaningful validation of the Recursion OS,” said Chris Gibson, Ph.D., Co–Founder and CEO of Recursion. “An unbiased phenotypic insight from our platform and driven by AI—linking MEK1/2 inhibition to APC loss–of–function biology—has now translated into rapid, substantial, and durable reductions in polyp burden in patients. This is a powerful example of how even the earliest versions of the Recursion OS can uncover therapeutic opportunities in diseases with no approved pharmacotherapy options. And since this discovery, we’ve only added to the breadth, depth, and power of the Recursion OS; we believe this is the first of many potential medicines that will advance as our flywheel of discovery accelerates.”

In the Phase 2 portion of the study, REC–4881 demonstrated rapid and durable reductions in polyp burden, with 43% median reduction in evaluable patients after 12 weeks of treatment. 75% of evaluable patients had a reduction in polyp burden in this same period. Importantly, the effect persisted well beyond the dosing period: 82% of evaluable patients (9 of 11) maintained reductions at Week 25—12 weeks after stopping therapy—with a 53% median decrease from baseline. These results are especially meaningful when considered alongside real–world natural history analyses showing that untreated FAP patients are expected to experience increases when left untreated.

“This program reflects a full validation cycle of the Recursion OS: an unbiased phenotypic signal identifying MEK1/2 inhibition as a rescue mechanism for APC loss–of–function, followed by mechanistic confirmation, clinical translation, and now encouraging human data in a disease with no approved medical therapies,” said Najat Khan, Ph.D., Chief R&D and Commercial Officer and incoming President and CEO. “REC–4881, an allosteric MEK1/2 inhibitor, represents a first precision–medicine approach for the causal biology of FAP. In TUPELO, we are seeing rapid, substantial, and durable reductions in polyp burden — including sustained benefit after patients stop therapy. Equally important, our ClinTech and real–world data capabilities have been instrumental in guiding this program — from refining eligibility to contextualizing a single–arm dataset with a first–of–its–kind natural history study.”

About FAP

FAP is one of the most clinically significant hereditary colorectal cancer syndromes and is caused by inactivating mutations in the APC gene, leading to the growth of hundreds to thousands of gastrointestinal polyps and a near 100% risk of developing colorectal cancer before the age of 40 if left untreated. With no approved pharmacotherapies, excisions followed sequentially by debilitating, life altering surgeries remain the only option to remove polyps and polyp burdened organs, typically involving colectomy in the early 20s. While this procedure removes immediate colon cancer risk, it does not address the underlying disease biology and does not prevent future polyp formation. Patients will continue to develop polyps in the rectum or upper GI tract, with approximately 50% of patients requiring subsequent life–altering surgical procedures to manage the persistent disease. Current treatment approaches lead to substantial long–term loss of quality of life, affecting continence, fertility, and long–term gastrointestinal function in relatively young patients. Approximately 90% of FAP patients go on to develop duodenal adenomas, with 6% eventually undergoing a high–morbidity risk duodenectomy to control polyp growth. FAP affects an estimated >50,000 individuals across the US and EU5 (France, Germany, Italy, Spain, and the UK).

Background on REC–4881 and Recursion’s Platform Insights

REC–4881 was discovered using one of the earliest versions of the Recursion OS (v0.1), through an unbiased, high–content AI–driven phenotypic screening approach in APC–deficient human cell models. Because FAP is driven by loss–of–function mutations in the APC gene, the platform was designed to identify molecules capable of rescuing APC–dependent biology—guided entirely by cellular phenotype, without presupposing any specific mechanism. Using AI/ML to extract and compare over a thousand morphological features that distinguish “diseased” from “healthy” states, the Recursion OS screened numerous investigative compounds and identified REC–4881 as one of the most robust phenotype–rescuing hits. In follow–up assays, REC–4881 consistently reverted APC–deficient cells toward a healthy–state phenotype and demonstrated potent, selective, and concentration–dependent MEK1/2 inhibition that was not seen across hundreds of other oncogenes and tumor suppressor models tested.

Importantly, the Recursion OS highlighted MEK1/2 inhibition as a mechanistic strategy to exploit a therapeutic vulnerability arising from APC loss in FAP—a disease area where MEK1/2 inhibition had not previously been investigated as a therapeutic strategy in a clinical setting. Based on this novel insight, Recursion in–licensed REC–4881 from Takeda, where it had been evaluated in solid tumors, and redirected it as the first MEK1/2 inhibitor advanced clinically for FAP. This program represents the power of a phenotype–first AI–driven discovery model: the platform surfaced a mechanistically aligned therapeutic opportunity solely through scaled high–dimensional exploration.

Today, the Company is using the Recursion OS 2.0 platform—including proprietary ClinTech capabilities of large–scale real–world evidence (RWE) analytics—to further advance the REC–4881 program. This includes a comprehensive natural history collaboration with Amsterdam University Medical Center, home to one of the largest and longest–running FAP registries, as well as analysis of more than 1,000 US FAP patients and 250,000 physician notes processed through Recursion’s custom LLM–based pipeline. Together, these data reinforce the relentlessly progressive nature of FAP, highlight the absence of spontaneous polyp regression, and demonstrate the substantial burden of repeated polyp–removal procedures and major surgeries experienced by real–world patients.

ClinTech insights also helped refine the design of the ongoing TUPELO trial, including expanding age eligibility from ≥55 to ≥18. This expansion was based on a thorough risk–benefit analysis, enabling evaluation of REC–4881 in younger patients who represent a substantial portion of FAP patients. REC–4881 has received Fast Track and Orphan Drug designations from the US FDA, as well as Orphan Drug designation from the European Commission.

Results of the Phase 2 Data for Ongoing REC–4881 Trial

Efficacy and Durability Findings

As of the November 25, 2025 data cutoff in the open–label Phase 2 portion of TUPELO, treatment with REC–4881 (4 mg QD) demonstrated meaningful and durable reductions in polyp burden in patients with FAP.

Week 13 Assessment

  • REC–4881 produced a median 43% reduction in total polyp burden among 12 efficacy–evaluable patients.
  • The majority of evaluable patients responded, with 75% showing reductions in polyp burden after 12 weeks of therapy.
  • 40% of patients (4 out of 10) achieved a ≥1–point improvement in Spigelman stage—a clinically meaningful measure of upper GI disease severity to assess surveillance and clinical management.
  • Other investigational agents currently under evaluation in separate studies generated approximately 17–29% median reduction in polyp burden after 12 months of treatment; no off–treatment durability was reported (Biodexa press release, June 24 2024)

Figure 1: Waterfall plot showing percent change from baseline in total polyp burden at Week 13 for efficacy–evaluable patients receiving REC–4881 (4 mg QD)

Week 25 Assessment

  • After 12 weeks of treatment, patients went off treatment for an additional 12–weeks. Durability of effect was maintained during the off–treatment observation period with 82% of patients responding (>0% reduction; 9 out of 11) at Week 25.
  • 73% achieved durable ≥30% reductions in polyp burden with a 53% median reduction in total polyp burden observed.
  • 40% of patients (4 out of 10) maintained a ≥1–point improvement in Spigelman stage from baseline.

Figure 2: Waterfall plot showing percent change from baseline in total polyp burden at Week 25 for efficacy–evaluable patients receiving REC–4881 (4 mg QD)

Safety Summary

As of the data cutoff, treatment with 4 mg REC–4881 demonstrated a safety profile generally consistent with prior MEK1/2 inhibitors.

  • Across the combined Phase 1b and Phase 2 safety cohorts (n=19), 94.7% of patients reported at least one treatment–related adverse event (TRAE), the majority of which were Grade 1/2 in severity. The most frequent TRAEs (≥10%) included: dermatitis acneiform / rash and blood CPK increase.
  • Grade 3 TRAEs occurred in 15.8% of patients; no Grade ≥4 TRAEs have been reported to date.
  • Treatment modifications were infrequent, with 2 of 19 patients experiencing dose interruption.

Figure 3: Summary of adverse events across Phase 1b and Phase 2 of the TUPELO trial

About the TUPELO Trial Design and Expanded Population
The Phase 1b/2 TUPELO trial is evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of REC–4881 monotherapy in patients with familial adenomatous polyposis (FAP).

Study Design and Analysis

Efficacy is assessed via upper and lower endoscopy at baseline, Week 13 (on–treatment), and Week 25 (off–treatment).

  • The primary endpoint is percent change from baseline in polyp burden, which is the sum of all polyp diameters in the GI.
  • The Efficacy Evaluable Population includes patients with measurable disease at baseline who received ≥75% of study drug and had at least one post–baseline endoscopic assessment. Disease staging uses the Spigelman system for upper GI polyposis and the InSiGHT classification for the lower GI tract.

Natural History Analyses
To better understand the natural history of FAP and to contextualize the single–arm efficacy of REC–4881, we collaborated with Amsterdam University Medical Center to analyze a registry of ~200 patients with FAP. 55 of these patients met the key inclusion criteria of TUPELO. We also leveraged our clinical development technology (ClinTech) platform to analyze US electronic health records (EHR), including physician notes, of ~1,000 FAP patients to assess disease progression and treatment patterns in the US. Both studies revealed high patient burden and progressive natural history of the disease. Results of the studies suggest that the natural history of FAP is to progress with relentless precancerous polyp progression: 87% of untreated patients in the registry experienced annualized increase in polyp burden. 10% were stable and 3% experienced a modest decrease in polyp burden. Mean increase of 60% and median increase of 28% in annualized polyp burden was observed. At least 75% of patients in the US EHR database had a major invasive surgery along with frequent polypectomies during follow–up.

Next Steps
Recursion plans to expand the population from ≥55 to ≥18 years old and further optimize dosing schedule. In parallel, the Company intends to engage the FDA in 1H26 to define a potential registration pathway.

Forward Looking Statements
This document contains information that includes or is based upon “forward–looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s anticipated engagement with the FDA; the clinical relevance of the TUPELO trial data and obtaining additional confirmatory data; advancing potential transformational therapies for FAP and beyond; subsequent REC–4881 studies, including expanded enrollment and alternate dosing schedule, and their results and advancing Recursion’s REC–4881 program further; the size of the potential FAP patient population; Recursion OS and other technologies potential and advancement of the future of medicine; business and financial plans and performance; and all other statements that are not historical facts. Forward–looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10–K and Quarterly Reports on Form 10–Q. All forward–looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine–learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.

Media Contact
[email protected]
Investor Contact
[email protected]

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/90547447–2b14–4969–a01f–353dfb0791aa
https://www.globenewswire.com/NewsRoom/AttachmentNg/057c1c25–0ed9–49f4–9e4b–2a7d3c9a234b
https://www.globenewswire.com/NewsRoom/AttachmentNg/b18bfe03–6a45–4ab5–bbe5–cfa957b1ad67


GLOBENEWSWIRE (Distribution ID 9598312)

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont–Saint–Guibert (Belgium), December 2, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below.

Robert Taub / BMI Estate

On November 27, 2025, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,290,800 voting rights, consisting of 4,240,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 9.97% of the total number of voting rights on November 20, 2025 (43,026,460).

The notification dated November 27, 2025 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Robert Taub
    • BMI Estate (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
  • Date on which the threshold was crossed: November 20, 2025
  • Threshold that is crossed: 10%
  • Denominator: 43,026,460
  • Notified details:
A) Voting rights Previous notification After the transaction
  # of voting rights # of voting rights % of voting rights
Holders of voting rights   Linked to securities Not linked to the securities Linked to securities Not linked to the securities
Robert Taub 2,121,470 2,712,510   6.30%  
BMI Estate 0 567,484   1.32%  
Robelga SRL 696,000 960,806   2,23%  
Subtotal 2,817,470 4,240,800   9.86%  
  TOTAL 4,240,800 0 9.86% 0.00%

B) Equivalent financial instruments After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
Robert Taub Warrants 08/06/2027   25,000 0.06% cash
Robert Taub Warrants 14/06/2028   25,000 0.06% cash
  TOTAL     50,000 0.12%  

  TOTAL (A & B) # of voting rights % of voting rights  
        4,290,800 9.97%  
  • Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.

Robert Taub / BMI Estate

On December 2, 2025, Nyxoah received a transparency notification from Robert Taub and related entity BMI Estate. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 10.14% of the total number of voting rights on December 1, 2025 (43,026,460).

The notification dated December 2, 2025 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Robert Taub
    • BMI Estate (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
  • Date on which the threshold was crossed: December 1, 2025
  • Threshold that is crossed: 10%
  • Denominator: 43,026,460
  • Notified details:
A) Voting rights Previous notification After the transaction
  # of voting rights # of voting rights % of voting rights
Holders of voting rights   Linked to securities Not linked to the securities Linked to securities Not linked to the securities
Robert Taub 2,712,510 2,712,510   6.30%  
BMI Estate 567,484 567,484   1.32%  
Robelga SRL 960,806 1,030,806   2.40%  
Subtotal 4,240,800 4,310,800   10.02%  
  TOTAL 4,310,800 0 10.02% 0.00%

B) Equivalent financial instruments After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
Robert Taub Warrants 08/06/2027   25,000 0.06% cash
Robert Taub Warrants 14/06/2028   25,000 0.06% cash
  TOTAL     50,000 0.12%  

  TOTAL (A & B) # of voting rights % of voting rights  
        4,360,800 10.14%  
  • Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001142526)

Publication relative à des notifications de transparence

        

INFORMATION RÉGLEMENTÉE

Publication relative à des notifications de transparence

Mont–Saint–Guibert (Belgique), le 2 décembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu deux notifications de transparence comme détaillées ci–dessous.

Robert Taub / BMI Estate

Le 27 novembre 2025, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, BMI Estate. Sur la base de la notification, Robert Taub (avec ses entreprises contrôlées) détient 4.290.800 droits de vote, soit 4.240.800 droits de vote attachés à des titres et 50.000 instruments financiers assimilés, représentant 9,97% du nombre total des droits de vote en date du 20 novembre 2025 (43.026.460).

La notification datée du 27 novembre 2025 contient les informations suivantes :

  • Motif de la notification : franchissement de seuil passif
  • Notification par : une entreprise mère ou une personne détenant le contrôle
  • Personnes tenues à la notification :
    • Robert Taub
    • BMI Estate (avec adresse à Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
  • Date du dépassement de seuil : le 20 novembre 2025
  • Seuil franchi : 10%
  • Dénominateur : 43.026.460
  • Détails de la notification :
A) Droits de vote Notification précédente Après la transaction
  # droits de vote # droits de vote % de droits de vote
Détenteurs de droits de vote   Attachés à des titres Non liés à des titres Attachés à des titres Non liés à des titres
Robert Taub 2.121.470 2.712.510   6,30%  
BMI Estate 0 567.484   1,32%  
Robelga SRL 696.000 960.806   2,23%  
Sous–total 2.817.470 4.240.800   9,86%  
  TOTAL 4.240.800 0 9,86% 0 ,00%

B) Instruments financiers assimilés Après la transaction
Détenteurs d’instruments financiers assimilés Type d’instrument financier Date d’échéance Date ou délai d’exercice ou de conversion # droits de vote pouvant être acquis en cas d’exercice de l’instrument % de droits de vote Règlement
Robert Taub Droits de souscription 08/06/2027   25.000 0,06% en espèces
Robert Taub Droits de souscription 14/06/2028   25.000 0,06% en espèces
  TOTAL     50.000 0,12%  

  TOTAL (A & B) # droits de vote % de droits de vote  
        4.290.800 9,97%  
  • Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Robelga SRL est 100% propriété de BMI Estate (société simple sans personnalité juridique). Robert Taub a 100% l'usufruit et les enfants de Robert Taub ont 100% la nue–propriété de BMI Estate.

Robert Taub / BMI Estate

Le 2 décembre 2025, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, BMI Estate. Sur la base de la notification, Robert Taub (avec ses entreprises contrôlées) détient 4.360.800 droits de vote, soit 4.310.800 droits de vote attachés à des titres et 50.000 instruments financiers assimilés, représentant 10,14% du nombre total des droits de vote en date du 1er décembre 2025 (43.026.460).

La notification datée du 2 décembre 2025 contient les informations suivantes :

  • Motif de la notification : acquisition ou cession de titres conférant le droit de vote ou de droits de vote
  • Notification par : une entreprise mère ou une personne détenant le contrôle
  • Personnes tenues à la notification :
    • Robert Taub
    • BMI Estate (avec adresse à Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
  • Date du dépassement de seuil : le 1er décembre 2025
  • Seuil franchi : 10%
  • Dénominateur : 43.026.460
  • Détails de la notification :
A) Droits de vote Notification précédente Après la transaction
  # droits de vote # droits de vote % de droits de vote
Détenteurs de droits de vote   Attachés à des titres Non liés à des titres Attachés à des titres Non liés à des titres
Robert Taub 2.712.510 2.712.510   6,30%  
BMI Estate 567.484 567.484   1,32%  
Robelga SRL 960.806 1.030.806   2,40%  
Sous–total 4.240.800 4.310.800   10,02%  
  TOTAL 4.310.800 0 10,02% 0,00%

B) Instruments financiers assimilés Après la transaction
Détenteurs d’instruments financiers assimilés Type d’instrument financier Date d’échéance Date ou délai d’exercice ou de conversion # droits de vote pouvant être acquis en cas d’exercice de l’instrument % de droits de vote Règlement
Robert Taub Droits de souscription 08/06/2027   25.000 0,06% en espèces
Robert Taub Droits de souscription 14/06/2028   25.000 0,06% en espèces
  TOTAL     50.000 0,12%  

  TOTAL (A & B) # droits de vote % de droits de vote  
        4.360.800 10,14%  
  • Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Robelga SRL est 100% propriété de BMI Estate (société simple sans personnalité juridique). Robert Taub a 100% l'usufruit et les enfants de Robert Taub ont 100% la nue–propriété de BMI Estate.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Pièces jointes


GLOBENEWSWIRE (Distribution ID 1001142526)